Irenic Capital Acquires $99.11 Million Stake in Integer Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy ITGR?
Source: Fool
- New Position Disclosure: On February 17, 2026, Irenic Capital Management LP disclosed a new position by acquiring 1,263,663 shares of Integer Holdings, with an estimated trade value of $99.11 million, highlighting its significant investment in the company.
- Holding Proportion Analysis: This acquisition positions Irenic's stake in Integer Holdings at 13.7% of its total assets under management, reflecting confidence in the company's growth potential despite a 37.9% decline in the stock over the past year.
- Financial Performance Overview: Integer Holdings achieved an 8% sales growth in 2025, reaching $1.85 billion in revenue, with a 21% increase in adjusted EPS to $6.40, and despite pressures from debt conversion costs, management remains optimistic about 2026.
- Market Outlook: Management projects adjusted EPS for 2026 to be between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027, indicating long-term investment potential in the cardiac and vascular sectors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ITGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to fall
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 86.680
Low
75.00
Averages
86.25
High
95.00
Current: 86.680
Low
75.00
Averages
86.25
High
95.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into Integer Holdings Board for Fiduciary Breach
- Sales Guidance Cut: On October 23, 2025, Integer Holdings Corporation lowered its full-year 2025 sales guidance to between $1.840 billion and $1.854 billion, falling short of prior expectations, indicating significant market challenges and sluggish growth.
- Decline in New Product Sales: During the subsequent earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026, suggesting that market adoption has been slower than anticipated, which could adversely affect future revenues.
- Severe Market Reaction: This news caused Integer's stock price to plummet by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, directly impacting investor confidence and the company's market capitalization.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into whether Integer's board breached its fiduciary duties to shareholders, potentially leading to shareholder losses, and is calling on affected shareholders to participate in discussions.
See More
Five9 Securities Fraud Class Action Survives Dismissal Motion
- Lawsuit Survives: The securities fraud class action against Five9 has survived a motion to dismiss in federal court, indicating that plaintiffs allege executives failed to disclose underperformance, potentially leading to financial losses for shareholders.
- Misrepresentation of Performance: Plaintiffs claim that Five9 executives falsely represented the strength of new business bookings during the first half of 2024, forcing the company to cut its annual revenue guidance, which negatively impacts investor confidence.
- Shareholder Actions: Shareholders holding Five9 stock can seek corporate reforms and fund returns, reflecting a strong demand for improved governance and transparency, which may prompt the company to adopt stricter compliance measures.
- Legal Consequences: The progress of this case could negatively affect Five9's stock price, necessitating investor attention on subsequent legal proceedings and their potential impact on the company's operations.
See More
Investigation into Integer Holdings Board's Potential Breach of Fiduciary Duties
- Sales Guidance Cut: On October 23, 2025, Integer Holdings lowered its full-year sales guidance to a range of $1.840 billion to $1.854 billion, falling short of market expectations, indicating significant growth challenges that could undermine investor confidence.
- Declining Product Sales Forecast: During the earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026, suggesting slower market adoption than anticipated, which may lead to future revenue declines.
- Slowing Cardiovascular Growth: The anticipated slowdown in sales growth for the Cardio & Vascular segment due to declines in electrophysiology products is expected to persist into 2026, further impacting the company's overall performance.
- Significant Stock Price Drop: Following the announcement, Integer's stock price plummeted by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, resulting in substantial losses for investors.
See More
Irenic Capital Acquires $99.11 Million Stake in Integer Holdings
- New Position Disclosure: On February 17, 2026, Irenic Capital Management LP disclosed a new position by acquiring 1,263,663 shares of Integer Holdings, with an estimated trade value of $99.11 million, highlighting its significant investment in the company.
- Holding Proportion Analysis: This acquisition positions Irenic's stake in Integer Holdings at 13.7% of its total assets under management, reflecting confidence in the company's growth potential despite a 37.9% decline in the stock over the past year.
- Financial Performance Overview: Integer Holdings achieved an 8% sales growth in 2025, reaching $1.85 billion in revenue, with a 21% increase in adjusted EPS to $6.40, and despite pressures from debt conversion costs, management remains optimistic about 2026.
- Market Outlook: Management projects adjusted EPS for 2026 to be between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027, indicating long-term investment potential in the cardiac and vascular sectors.
See More
Irenic Capital Management Acquires Stake in Integer Holdings
- New Position Disclosure: Irenic Capital Management disclosed a new position in Integer Holdings by acquiring 1,263,663 shares in Q4 2026, valued at approximately $99.11 million, making it the fund's largest disclosed equity position, reflecting strong confidence in the company.
- Performance Growth: Integer Holdings achieved an 8% sales growth in 2025, reaching $1.85 billion, with a 21% increase in adjusted EPS to $6.40, showcasing the company's robust performance in the medical device sector.
- Future Outlook: Management anticipates adjusted EPS for 2026 to be between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027, indicating a positive outlook for the future.
- Portfolio Allocation: Irenic's stake in Integer Holdings represents 13.7% of its equity assets, which, while not dominant, aligns with its activist strategy targeting operationally solid companies to drive valuation and capital allocation catalysts.
See More
Newtyn Management Acquires Stake in Integer Holdings
- New Investment Disclosure: On February 17, 2026, Newtyn Management disclosed a new position by acquiring 550,000 shares of Integer Holdings for approximately $43.14 million, indicating confidence in the company despite its recent stock decline.
- Asset Allocation Insight: This acquisition represents 4.53% of Newtyn's 13F reportable assets, highlighting a strategic focus on the medical device sector, even as Integer Holdings' stock has fallen 37.9% over the past year.
- Financial Performance Highlights: Integer Holdings achieved an 8% year-over-year sales growth in 2025, reaching $1.85 billion in revenue, with a 21% increase in adjusted EPS to $6.40, demonstrating robust performance in the medical device market.
- Future Outlook: Despite facing approximately $1.19 billion in debt, management anticipates a leverage ratio between 2.5 and 3.5 times in 2026, with sales guidance suggesting flat to slightly declining GAAP revenue, while adjusted earnings are expected to remain stable, attracting long-term investor interest.
See More
Investigation into Integer Holdings Board for Fiduciary Breach
- Sales Guidance Cut: On October 23, 2025, Integer Holdings Corporation lowered its full-year 2025 sales guidance to between $1.840 billion and $1.854 billion, falling short of prior expectations, indicating significant market challenges and sluggish growth.
- Decline in New Product Sales: During the subsequent earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026, suggesting that market adoption has been slower than anticipated, which could adversely affect future revenues.
- Severe Market Reaction: This news caused Integer's stock price to plummet by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, directly impacting investor confidence and the company's market capitalization.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into whether Integer's board breached its fiduciary duties to shareholders, potentially leading to shareholder losses, and is calling on affected shareholders to participate in discussions.
See More
Five9 Securities Fraud Class Action Survives Dismissal Motion
- Lawsuit Survives: The securities fraud class action against Five9 has survived a motion to dismiss in federal court, indicating that plaintiffs allege executives failed to disclose underperformance, potentially leading to financial losses for shareholders.
- Misrepresentation of Performance: Plaintiffs claim that Five9 executives falsely represented the strength of new business bookings during the first half of 2024, forcing the company to cut its annual revenue guidance, which negatively impacts investor confidence.
- Shareholder Actions: Shareholders holding Five9 stock can seek corporate reforms and fund returns, reflecting a strong demand for improved governance and transparency, which may prompt the company to adopt stricter compliance measures.
- Legal Consequences: The progress of this case could negatively affect Five9's stock price, necessitating investor attention on subsequent legal proceedings and their potential impact on the company's operations.
See More
Investigation into Integer Holdings Board's Potential Breach of Fiduciary Duties
- Sales Guidance Cut: On October 23, 2025, Integer Holdings lowered its full-year sales guidance to a range of $1.840 billion to $1.854 billion, falling short of market expectations, indicating significant growth challenges that could undermine investor confidence.
- Declining Product Sales Forecast: During the earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026, suggesting slower market adoption than anticipated, which may lead to future revenue declines.
- Slowing Cardiovascular Growth: The anticipated slowdown in sales growth for the Cardio & Vascular segment due to declines in electrophysiology products is expected to persist into 2026, further impacting the company's overall performance.
- Significant Stock Price Drop: Following the announcement, Integer's stock price plummeted by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, resulting in substantial losses for investors.
See More
Irenic Capital Acquires $99.11 Million Stake in Integer Holdings
- New Position Disclosure: On February 17, 2026, Irenic Capital Management LP disclosed a new position by acquiring 1,263,663 shares of Integer Holdings, with an estimated trade value of $99.11 million, highlighting its significant investment in the company.
- Holding Proportion Analysis: This acquisition positions Irenic's stake in Integer Holdings at 13.7% of its total assets under management, reflecting confidence in the company's growth potential despite a 37.9% decline in the stock over the past year.
- Financial Performance Overview: Integer Holdings achieved an 8% sales growth in 2025, reaching $1.85 billion in revenue, with a 21% increase in adjusted EPS to $6.40, and despite pressures from debt conversion costs, management remains optimistic about 2026.
- Market Outlook: Management projects adjusted EPS for 2026 to be between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027, indicating long-term investment potential in the cardiac and vascular sectors.
See More
Irenic Capital Management Acquires Stake in Integer Holdings
- New Position Disclosure: Irenic Capital Management disclosed a new position in Integer Holdings by acquiring 1,263,663 shares in Q4 2026, valued at approximately $99.11 million, making it the fund's largest disclosed equity position, reflecting strong confidence in the company.
- Performance Growth: Integer Holdings achieved an 8% sales growth in 2025, reaching $1.85 billion, with a 21% increase in adjusted EPS to $6.40, showcasing the company's robust performance in the medical device sector.
- Future Outlook: Management anticipates adjusted EPS for 2026 to be between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027, indicating a positive outlook for the future.
- Portfolio Allocation: Irenic's stake in Integer Holdings represents 13.7% of its equity assets, which, while not dominant, aligns with its activist strategy targeting operationally solid companies to drive valuation and capital allocation catalysts.
See More
Newtyn Management Acquires Stake in Integer Holdings
- New Investment Disclosure: On February 17, 2026, Newtyn Management disclosed a new position by acquiring 550,000 shares of Integer Holdings for approximately $43.14 million, indicating confidence in the company despite its recent stock decline.
- Asset Allocation Insight: This acquisition represents 4.53% of Newtyn's 13F reportable assets, highlighting a strategic focus on the medical device sector, even as Integer Holdings' stock has fallen 37.9% over the past year.
- Financial Performance Highlights: Integer Holdings achieved an 8% year-over-year sales growth in 2025, reaching $1.85 billion in revenue, with a 21% increase in adjusted EPS to $6.40, demonstrating robust performance in the medical device market.
- Future Outlook: Despite facing approximately $1.19 billion in debt, management anticipates a leverage ratio between 2.5 and 3.5 times in 2026, with sales guidance suggesting flat to slightly declining GAAP revenue, while adjusted earnings are expected to remain stable, attracting long-term investor interest.
See More
